Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

Next Previous
Trial Profile

A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 01 Dec 2021 Results of an updated results on safety and efficacy with a median follow-up of 22 months and provide the findings on the secondary endpoints not previously reported published in the Oncologist
  • 13 Feb 2021 Final safety and efficacy results of this trial presented at the 2021 Genitourinary Cancers Symposium
  • 15 Feb 2020 Primary endpoint (Safety and feasibility of combining Ra-223+Enza) has been met as per results presented at the 2020 Genitourinary Cancers Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top